Insmed (INSM) Misses Q1 EPS by 1c

Insmed (NASDAQ: INSM) reported Q1 EPS of ($0.96), $0.01 worse than the analyst estimate of ($0.95). Revenue for the quarter came in at $21.9 million versus the consensus estimate of $19.62 million.

The Company now expects full-year 2019 revenues for ARIKAYCE to be in the range of $90 million to $105 million.

For earnings history and earnings-related data on Insmed (INSM) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance
• Norwegian Cruise Line rating cut at Mizuho after 'self-inflicted wounds'